Frontiers in Immunology (Mar 2019)
Seminal Plasma Exposures Strengthen Vaccine Responses in the Female Reproductive Tract Mucosae
- Romain Marlin,
- Romain Marlin,
- Romain Marlin,
- Marie-Thérèse Nugeyre,
- Marie-Thérèse Nugeyre,
- Marie-Thérèse Nugeyre,
- Nicolas Tchitchek,
- Matteo Parenti,
- Matteo Parenti,
- Cécile Lefebvre,
- Cécile Lefebvre,
- Hakim Hocini,
- Hakim Hocini,
- Fahd Benjelloun,
- Fahd Benjelloun,
- Claude Cannou,
- Claude Cannou,
- Silvia Nozza,
- Nathalie Dereuddre-Bosquet,
- Yves Levy,
- Yves Levy,
- Yves Levy,
- Françoise Barré-Sinoussi,
- Françoise Barré-Sinoussi,
- Gabriella Scarlatti,
- Gabriella Scarlatti,
- Roger Le Grand,
- Roger Le Grand,
- Elisabeth Menu,
- Elisabeth Menu,
- Elisabeth Menu
Affiliations
- Romain Marlin
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
- Romain Marlin
- MISTIC Group, Department of Virology, Institut Pasteur, Paris, France
- Romain Marlin
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
- Marie-Thérèse Nugeyre
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
- Marie-Thérèse Nugeyre
- MISTIC Group, Department of Virology, Institut Pasteur, Paris, France
- Marie-Thérèse Nugeyre
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
- Nicolas Tchitchek
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
- Matteo Parenti
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
- Matteo Parenti
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
- Cécile Lefebvre
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
- Cécile Lefebvre
- Équipe 16 Physiopathologie et Immunothérapies dans l'Infection VIH, Institut Mondor de Recherche Biomédicale - INSERM U955, Créteil, France
- Hakim Hocini
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
- Hakim Hocini
- Équipe 16 Physiopathologie et Immunothérapies dans l'Infection VIH, Institut Mondor de Recherche Biomédicale - INSERM U955, Créteil, France
- Fahd Benjelloun
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
- Fahd Benjelloun
- MISTIC Group, Department of Virology, Institut Pasteur, Paris, France
- Claude Cannou
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
- Claude Cannou
- MISTIC Group, Department of Virology, Institut Pasteur, Paris, France
- Silvia Nozza
- Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
- Nathalie Dereuddre-Bosquet
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
- Yves Levy
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
- Yves Levy
- Équipe 16 Physiopathologie et Immunothérapies dans l'Infection VIH, Institut Mondor de Recherche Biomédicale - INSERM U955, Créteil, France
- Yves Levy
- Groupe Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France
- Françoise Barré-Sinoussi
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
- Françoise Barré-Sinoussi
- International Division, Institut Pasteur, Paris, France
- Gabriella Scarlatti
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
- Gabriella Scarlatti
- Viral Evolution and Transmission Unit, San Raffaele Scientific Institute, Milan, Italy
- Roger Le Grand
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
- Roger Le Grand
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
- Elisabeth Menu
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
- Elisabeth Menu
- MISTIC Group, Department of Virology, Institut Pasteur, Paris, France
- Elisabeth Menu
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
- DOI
- https://doi.org/10.3389/fimmu.2019.00430
- Journal volume & issue
-
Vol. 10
Abstract
HIV-1 sexual transmission occurs mainly via mucosal semen exposures. In the female reproductive tract (FRT), seminal plasma (SP) induces physiological modifications, including inflammation. An effective HIV-1 vaccine should elicit mucosal immunity, however, modifications of vaccine responses by the local environment remain to be characterized. Using a modified vaccinia virus Ankara (MVA) as a vaccine model, we characterized the impact of HIV-1+ SP intravaginal exposure on the local immune responses of non-human primates. Multiple HIV-1+ SP exposures did not impact the anti-MVA antibody responses. However, SP exposures revealed an anti-MVA responses mediated by CD4+ T cells, which was not observed in the control group. Furthermore, the frequency and the quality of specific anti-MVA CD8+ T cell responses increased in the FRT exposed to SP. Multi-parameter approaches clearly identified the cervix as the most impacted compartment in the FRT. SP exposures induced a local cell recruitment of antigen presenting cells, especially CD11c+ cells, and CD8+ T cell recruitment in the FRT draining lymph nodes. CD11c+ cell recruitment was associated with upregulation of inflammation-related gene expression after SP exposures in the cervix. We thus highlight the fact that physiological conditions, such as SP exposures, should be taken into consideration to test and to improve vaccine efficacy against HIV-1 and other sexually transmitted infections.
Keywords